Health Rounds: Roche/BioNTech experimental vaccine shows early promise in pancreatic cancer

Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following surgery in a small, early trial were still alive, most without disease recurrence, more than three years later, researchers reported. Typically, the rare long-term survivors of this disease have immune systems that learn to recognize and attack mutant proteins, or neoantigens, in their cancer cells, the study authors noted in a commentary published with their report.

Čítajte ďalej na https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-rochebiontech-experimental-vaccine-shows-early-promise-pancreatic-2025-03-05/